Recombinant Anti-PI3 Kinase p110 beta antibody [Y384] (ab32569)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [Y384] to PI3 Kinase p110 beta
- Suitable for: WB, IP
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-PI3 Kinase p110 beta antibody [Y384]
See all PI3 Kinase p110 beta primary antibodies -
Description
Rabbit monoclonal [Y384] to PI3 Kinase p110 beta -
Host species
Rabbit -
Specificity
ab32569 recognises PI3-Kinases (PI3-Ks). -
Tested applications
Suitable for: WB, IPmore details
Unsuitable for: Flow Cyt (Intra),ICC or ICC/IF -
Species reactivity
Reacts with: Human
Predicted to work with: Guinea pig, Cow, Cat, Dog, Pig -
Immunogen
Synthetic peptide within Human PI3 Kinase p110 beta. The exact sequence is proprietary.
-
Positive control
- WB: Jurkat whole cell lysate (ab7899). IP: Jurkat
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
Y384 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab32569 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/500. Detects a band of approximately 110 kDa (predicted molecular weight: 123 kDa).
|
IP |
1/50.
|
Notes |
---|
WB
1/500. Detects a band of approximately 110 kDa (predicted molecular weight: 123 kDa). |
IP
1/50. |
Target
-
Function
Phosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2. -
Tissue specificity
Expressed ubiquitously. -
Pathway
Phospholipid metabolism; phosphatidylinositol phosphate biosynthesis. -
Sequence similarities
Belongs to the PI3/PI4-kinase family.
Contains 1 PI3K/PI4K domain. - Information by UniProt
-
Database links
- Entrez Gene: 517948 Cow
- Entrez Gene: 5291 Human
- Omim: 602925 Human
- SwissProt: P42338 Human
- Unigene: 239818 Human
-
Alternative names
- 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta antibody
- 5-bisphosphate 3-kinase catalytic subunit beta isoform antibody
- DKFZp779K1237 antibody
see all
Images
-
Lane 1: Wild-type HAP1 cell lysate (40 µg)
Lane 2: PI3 Kinase p110 beta knockout HAP1 cell lysate (40 µg)
Lane 3: Jurkat cell lysate (40 µg)
Lane 4: K562 cell lysate (40 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab32569 observed at 125 kDa. Red - loading control, ab8245, observed at 37 kDa.ab32569 was shown to recognize PI3 Kinase p110 beta when PI3 Kinase p110 beta knockout samples were used, along with additional cross-reactive bands. Wild-type and PI3 Kinase p110 beta knockout samples were subjected to SDS-PAGE. Ab32569 and ab8245 (loading control to GAPDH) were diluted at 1/500 and 1/10,000 dilution respectively and incubated overnight at 4C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
-
Anti-PI3 Kinase p110 beta antibody [Y384] (ab32569) at 1/500 dilution + Jurkat cell lysate
Predicted band size: 123 kDa
Observed band size: 110 kDa why is the actual band size different from the predicted? -
PI3 Kinase p110 beta was immunoprecipitated from 0.35 mg Jurkat (Human T cell leukemia T lymphocyte) whole cell lysate 10 µg with ab32569 at 1/50 dilution (2µg). VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: Jurkat (Human T cell leukemia T lymphocyte) whole cell lysate 10 µg
Lane 2: ab32569 IP in Jurkat whole cell lysate
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab32569 in Jurkat whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (15)
ab32569 has been referenced in 15 publications.
- Hong S et al. Ginsenoside Rg3 enhances the anticancer effect of 5-FU in colon cancer cells via the PI3K/AKT pathway. Oncol Rep 44:1333-1342 (2020). PubMed: 32945504
- Romeo V et al. Effects of PI3K Inhibition on Afucosylated Antibody-Driven Fc?RIIIa Events and Phospho-S6 Activity in NK Cells. J Immunol 203:137-147 (2019). PubMed: 31092639
- Li P et al. Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma. Med Sci Monit 24:623-635 (2018). PubMed: 29384143
- Yang Y et al. Microarray pathway analysis indicated that mitogen-activated protein kinase/extracellular signal-regulated kinase and insulin growth factor 1 signaling pathways were inhibited by small interfering RNA against AT-rich interactive domain 1A in endometrial cancer. Oncol Lett 15:1829-1838 (2018). PubMed: 29399196
- Si F et al. MicroRNA-138 suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting EZH2 and PI3K/AKT signaling. Exp Ther Med 14:1967-1974 (2017). PubMed: 28962111